Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Refractory Metastatic GIST
NCT02776878Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in gastrointestinal stromal tumor (GIST), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
dasatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02776878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776878.